ELSA (EarLy Surveillance for Autoimmune diabetes)
University of Birmingham (co-funded by Diabetes UK and Breakthrough T1D)
What it is
ELSA studies whether UK childhood screening for early type 1 diabetes is feasible and acceptable. The current program covers ages 2–17, but its official website says screening is paused. Published case-series findings do not establish a guaranteed reduction in DKA or a national screening service.
Editorial review: .
Most recent recorded citation date: 2026-03-02. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Predictive value: The protocol describes islet-autoantibody testing followed by confirmation and metabolic staging. Test performance and future progression risk are different questions.[2]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Official study site says recruitment is paused; no reopening date givenApproval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 88 × 25 + 86 × 25 + 90 × 20 + 85 × 15 + 25 × 15 = 7800; divide by total weight 100. Unrounded weighted result: 78.
The protocol describes islet-autoantibody testing followed by confirmation and metabolic staging. Test performance and future progression risk are different questions.[2]
Screening can lead to education and follow-up. In a small case series, eight children completing screening avoided DKA; two others developed DKA before confirmation. This is not a randomized effect estimate.[3]
The expanded program covers UK children aged 2–17 regardless of family history; participation is currently paused. Broad intended reach is not actual uptake.[1]
Initial sampling can use a finger-prick at home or in community or clinical settings. Positive screens require venous confirmation and sometimes glucose testing; anxiety and follow-up burden matter.[2]
The official study site says screening is paused and offers reopening notifications. No reopening date is given.[1]
Editor’s take
Useful evidence about how a screening pathway might work, with access currently paused. The scores are editorial judgments about the program, not measured probabilities of benefit or national implementation.
The full picture
Participation now
The official ELSA website says screening is paused and offers notifications when it reopens. The expanded UK program covers ages 2–17; the original study covered ages 3–13. An older registry timetable does not establish that families can enroll today.17
What the study tests
ELSA examines the feasibility and acceptability of general-population screening. Its original protocol planned 20,000 children. Initial dried-blood-spot samples can be collected at home or in community and clinical settings. Positive autoantibody screens lead to venous confirmation; children with multiple antibodies are offered glucose testing for disease staging and education. The study also examines uptake, sample usability and families’ experiences, including anxiety. Screening itself is not treatment.2
The registry, last updated 12 August 2025, lists a revised target of 50,000 and completion planned for 31 August 2029. These are plans, not completed-screen counts. The university reported more than 37,000 families signed up by November 2025; that does not mean 37,000 blood screens were completed.47
Results and limits
A 2024 descriptive case series included 14 children diagnosed with stage 3 T1D during or after participation. Two developed DKA before antibody confirmation. All eight who completed screening before diagnosis avoided DKA. This small series has no randomized control group and cannot establish a guaranteed DKA benefit.3
A 2026 screening-results letter received a correction in March. The corrected full article and correction text were not accessible for this review, so their detailed screening-yield figures are not presented as verified findings here.56
Confirmatory tests and follow-up matter after screening, and a negative screen does not replace assessment of symptoms. The published case series describes children whose symptoms arose before screening was complete.3 See the ELSA trial record for study details and the screening index for other programs.
Coming soon
ETA · Reopening date not announced; contact the study team for a notification
- →Reopening of ELSA screening participation · No date announced
- →Expanded-program feasibility and acceptability follow-up · Registry completion planned for August 2029; this is not a results-publication date
Sources
- [1]The ELSA Study: current participation status · Open-source community — Checked 17 September 2026: screening paused; the page does not state when the pause began.
ELSA official program. Current pause notice, checked 17 September 2026.
- [2]Protocol for a feasibility and acceptability study for UK general population paediatric type 1 diabetes screening—the ELSA study · Peer-reviewed study · 2024-12-02
Quinn LM, et al. ELSA protocol. Diabetic Medicine, published online 2 December 2024.
- [3]Presentation and characteristics of children with screen-detected type 1 diabetes: learnings from the ELSA general population pediatric screening study · Peer-reviewed study · 2024-09-26
Quinn LM, et al. Original ELSA case series, 2024.
- [4]ISRCTN97974414: ELSA screening study · Trial registry · 2025-08-12
ISRCTN97974414. Registry updated 12 August 2025.
- [5]Feasibility of general population screening for type 1 diabetes in the UK: the ELSA study · Peer-reviewed study · 2026-01-20 — A correction was published online 2 March 2026. The corrected full text was not accessible in this review.
Quinn LM, et al. ELSA screening-results letter, 2026.
- [6]Correction to Lancet Diabetes Endocrinol 2026; 14: 197–99 · Peer-reviewed study · 2026-03-02
Correction, online 2 March 2026.
- [7]Childhood type 1 diabetes screening is effective and could prevent thousands of emergency diagnoses · Science journalism · 2026-01-20
University of Birmingham. ELSA expansion announcement, 20 January 2026.